Pharmas
You might want to consider implications of the pharma litigation currently underway in S Africa (for those not following the story, the rainbow government is contesting US pharma companies' legal defence of patents... has to do with attempts to offer drugs at realistic prices to African countries and, in particular, HIV-stricken SA). I agree with Darth, biotechs are probably worth a look at the NAS heads south for the summer (the NASDAQ listing of SkyePharma - not strictly a biotech play - listed as 'SKYE' in the US as a case in point. Broadly speaking tends to drift down during any advance and appreciate as investors seek the safety of more defensive plays.